Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panion & Bf BiotechTPE:1760 -0.51%75 EV-to-EBITDA is 10.92 as of Aug. 31, 2026, which is 52% below its 10-year median of 22.69. GuruFocus rates TPE:1760 with a GF Score™ of 75/100 and a GF Value™ of NT$86.45 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 730 Drug Manufacturers companies, Panion & Bf Biotech ranks better than 59.04% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Panion & Bf Biotech's enterprise value is NT$5,130 Mil.
Panion & Bf Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$470 Mil. Therefore, Panion & Bf Biotech's EV-to-EBITDA for today is 10.92.
The historical rank and industry rank for Panion & Bf Biotech's EV-to-EBITDA or its related term are showing as below:
TPE:1760'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.83 Med: 22.69 Max: 471.19
Current: 10.92
During the past 13 years, the highest EV-to-EBITDA of Panion & Bf Biotech was 471.19. The lowest was 10.83. And the median was 22.69.
TPE:1760's EV-to-EBITDA is ranked better than 59.04% of 730
companies
in the Drug Manufacturers industry
Industry Median: 13.47
vs TPE:1760: 10.92
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Panion & Bf Biotech's PE Ratio (TTM) for today is calculated as:
Panion & Bf Biotech's share price for today is NT$58.30.
Panion & Bf Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Panion & Bf Biotech's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Panion & Bf Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panion & Bf Biotech EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panion & Bf Biotech's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Panion & Bf Biotech's EV-to-EBITDA falls into.
Panion & Bf Biotech's current Enterprise Value is NT$5,130 Mil.
Panion & Bf Biotech's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$470 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panion & Bf Biotech (TPE:1760) has a EV-to-EBITDA of 10.92 as of Aug. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Panion & Bf Biotech. This is 52% below median its historical median of 22.69. Over the past decade, Panion & Bf Biotech's EV-to-EBITDA has ranged from 10.83 to 471.19. According to the industry distribution chart, Panion & Bf Biotech ranks #299 out of 730 companies in the Drug Manufacturers industry, placing it in the top 41%.
Is Panion & Bf Biotech's EV-to-EBITDA too high?
Panion & Bf Biotech's current EV-to-EBITDA of 10.92 is 52% below median its 10-year median of 22.69. Over the past 10 years, this metric has ranged from a low of 10.83 to a high of 471.19. The Drug Manufacturers industry median EV-to-EBITDA is 13.47. Panion & Bf Biotech's value of 10.92 is 18.9% below this industry median. Based on the distribution chart, Panion & Bf Biotech ranks #299 out of 730 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Panion & Bf Biotech has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Panion & Bf Biotech ranks #299 out of 730 companies for EV-to-EBITDA. This puts Panion & Bf Biotech in the upper half of its industry. The industry median EV-to-EBITDA is 13.47. Panion & Bf Biotech's value of 10.92 is 18.9% below this benchmark. Historically, Panion & Bf Biotech's own EV-to-EBITDA has ranged from 10.83 to 471.19 over the past decade. While the company's 10-year median is 22.69 vs. the industry median of 13.47, Panion & Bf Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.47, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panion & Bf Biotech's current EV-to-EBITDA of 10.92 is 18.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Panion & Bf Biotech. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panion & Bf Biotech's current EV-to-EBITDA is 10.92, which is 52% below median its own 10-year median of 22.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$86.45, compared to a current price of NT$58.30 — trading 32.6% below its estimated fair value. The current EV-to-EBITDA is 10.92, which is 52% below median its 10-year median of 22.69 and 18.9% below the Drug Manufacturers industry median of 13.47. Panion & Bf Biotech's overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current EV-to-EBITDA is 10.92 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?
Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued.
The current stock price of NT$58.30 is trading 32.6% below its estimated GF Value™ of NT$86.45.
GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1760:
EV-to-EBITDA: 10.92 (52% below median its 10-year median of 22.69)
GF Value™: NT$86.45 vs. price of NT$58.30 (32.6% below fair value)
Industry Position: 18.9% below the Drug Manufacturers median (#299 of 730)
No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
75GF Score
Get the complete analysis for TPE:1760
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1760 has been successfully added to your 
